<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac,d:00feedac202d479c8149ec5d91684529--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mnlo-20210506</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV80L2ZyYWc6MzU5Yjc2NzhlNWE4NGRhN2I0NzlmODliNTFhNmI4MWMvdGFibGU6YmFlNzEwMjVjNjUyNGNmNWFjMjQwNzVlMTg2Zjg5NTYvdGFibGVyYW5nZTpiYWU3MTAyNWM2NTI0Y2Y1YWMyNDA3NWUxODZmODk1Nl8wLTEtMS0xLTA_6570c9cd-5c02-437e-8881-3abc21ab68e8">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV80L2ZyYWc6MzU5Yjc2NzhlNWE4NGRhN2I0NzlmODliNTFhNmI4MWMvdGFibGU6YmFlNzEwMjVjNjUyNGNmNWFjMjQwNzVlMTg2Zjg5NTYvdGFibGVyYW5nZTpiYWU3MTAyNWM2NTI0Y2Y1YWMyNDA3NWUxODZmODk1Nl8xLTEtMS0xLTA_8193b06b-ae45-4276-b83a-ee4ef1a3c8aa">0001566044</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mnlo-20210506.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i00feedac202d479c8149ec5d91684529_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA1_07b8748a-e245-42b2-bf4b-b94f717e0874">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF80NDA_2b2e56bd-3459-4091-ad08-184bf7cf4e14">May&#160;6, 2021</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xNzk4_461e8cdf-fef4-432d-ac03-523cffa12b9d">VYNE Therapeutics Inc</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTAtMS0xLTA_40b8fbee-1dce-43f5-b4ea-8e9df114659a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTEtMS0xLTA_7632c04f-5b0c-4820-83c8-61c15c660bfe">001-38356</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTItMS0xLTA_92d7f462-c72a-415f-947e-504473fa0426">45-3757789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA2_3df3d713-fa8b-4fa6-9908-4bda7907e830">520 U.S. Highway 22, Suite 204</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xNzk5_67553aed-da69-4bb7-8ef7-0d45fede1fde">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAw_f7583db5-fd68-4f14-97a0-9e2bf40dba97">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA3_6fc95c90-75fd-4479-a4e8-2f060686779e">08807</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAx_15ffd636-c916-4d03-bb42-90726cb8bf91">800</ix:nonNumeric>) <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAy_8cdd7185-3568-4e99-bfa3-7c3a296097e0">775-7936</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K&#160;filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF8wLTEtMS0xLTA_2f4e0088-ba3d-40e8-9d48-d3ceb1686c15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF8yLTEtMS0xLTA_224454f6-82e9-439e-88d7-cf2c5f7da4b1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12&#160;under the Exchange Act (17 CFR&#160;240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF80LTEtMS0xLTA_5cdb1466-ca39-481e-96a3-9b0cab5fb4d1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR&#160;240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF82LTEtMS0xLTA_383bfa52-f5d1-4a02-a25f-bad369599a88">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTAtMS0xLTA_7504efec-1468-4cb1-a8a5-8879c7b291ad">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTItMS0xLTA_937191c1-096a-466d-891e-5a9de2965788">VYNE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTQtMS0xLTA_ee7f2207-fea9-4615-91f7-168b827c3fd8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter). Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA4_2629dcfb-9712-40da-8338-98577d9171b3">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAz_efc43d24-85f7-4391-86a1-544db63dc1bd">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i00feedac202d479c8149ec5d91684529_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6, 2021, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2021. The press release is being furnished as Exhibit 99.1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i00feedac202d479c8149ec5d91684529_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibit is being furnished herewith.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-2021506q1x2021exx991.htm">Press release, dated May 6, 2021.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i00feedac202d479c8149ec5d91684529_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xMy9mcmFnOjczNWQ5NjI4NTI0ODRlNjQ4NmExYjA5ZjA5ZjBiMmFiL3RhYmxlOjdiNzU1NjM1ODE1NDQxZjFiYzIzM2MwYmY3ZTAyNjE1L3RhYmxlcmFuZ2U6N2I3NTU2MzU4MTU0NDFmMWJjMjMzYzBiZjdlMDI2MTVfMi0wLTEtMS0w_2b2e56bd-3459-4091-ad08-184bf7cf4e14">May 6, 2021</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Mutya Harsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutya Harsch<br/>Chief Legal Officer and General Counsel</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "mnlo-20210506.htm", "description": "8-K", "secsgml_size_bytes": 34274}]
{"company-data": {"conformed-name": "VYNE Therapeutics Inc.", "cik": "0001566044", "assigned-sic": "2834", "irs-number": "453757789", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-38356", "film-number": "21895752"}, "business-address": {"street1": "520 U.S. HIGHWAY 22, SUITE 204", "city": "BRIDGEWATER", "state": "NJ", "zip": "08807", "phone": "800-775-7936"}, "mail-address": {"street1": "520 U.S. HIGHWAY 22, SUITE 204", "city": "BRIDGEWATER", "state": "NJ", "zip": "08807"}, "former-company": [{"former-conformed-name": "Menlo Therapeutics Inc.", "date-changed": "20180201"}, {"former-conformed-name": "Menlo Therapeutics, Inc.", "date-changed": "20170728"}, {"former-conformed-name": "Tigercat Pharma, Inc.", "date-changed": "20130104"}]}
mnlo-20210506
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________________________________________________________________
FORM
8-K
___________________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 6, 2021
___________________________________________________________________________________________________________
VYNE Therapeutics Inc
.
(Exact name of registrant as specified in its charter)
___________________________________________________________________________________________________________
Delaware
001-38356
45-3757789
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
520 U.S. Highway 22, Suite 204
Bridgewater
,
New Jersey
08807
(Address of principal executive offices, including Zip Code)
(
800
)
775-7936
(Registrant's telephone number, including area code)
___________________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.0001 par value
VYNE
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item 2.02 Results of Operations and Financial Condition.
On May 6, 2021, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2021. The press release is being furnished as Exhibit 99.1.
The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is being furnished herewith.
Exhibit No.
Description
99.1
Press release, dated May 6, 2021.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VYNE THERAPEUTICS INC
.
Date:
May 6, 2021
By:
/s/ Mutya Harsch
Mutya Harsch
Chief Legal Officer and General Counsel